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Abstract
Tumor vessels are characterized by abnormal morphology and hyper-permeability that together 
cause inefficient delivery of chemotherapeutic agents. Although VEGF has been established as a 
critical regulator of tumor angiogenesis, the role of mechanical signaling in the regulation of 
tumor vasculature or tumor endothelial cell (TEC) function is not known. Here, we show that the 
mechanosensitive ion channel TRPV4 regulates tumor angiogenesis and tumor vessel maturation 
via modulation of TEC mechanosensitivity. We found that TEC exhibit reduced TRPV4 
expression and function, which is correlated with aberrant mechanosensitivity towards ECM 
stiffness, increased migration and abnormal angiogenesis by TEC. Further, syngeneic tumor 
experiments revealed that the absence of TRPV4 induced increased vascular density, vessel 
diameter and reduced pericyte coverage resulting in enhanced tumor growth in TRPV4 KO mice. 
Importantly, overexpression or pharmacological activation of TRPV4 restored aberrant TEC 
mechanosensitivity, migration and normalized abnormal angiogenesis in vitro by modulating Rho 
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activity. Finally, a small molecule activator of TRPV4, GSK1016790A, in combination with anti-
cancer drug Cisplatin, significantly reduced tumor growth in WT mice by inducing vessel 
maturation. Our findings demonstrate TRPV4 channels to be critical regulators of tumor 
angiogenesis and represent a novel target for anti-angiogenic and vascular normalization therapies.
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 Introduction
Angiogenesis, the formation of new blood vessels from pre-existing capillaries, is critical for 
solid tumor maintenance, growth and progression as it ensures proper oxygen and nutrient 
delivery to the tumor. However, the tumor vasculature is structurally and functionally 
abnormal, as characterized by its high tortuosity, non-uniform pericyte coverage and hyper-
permeability1, 2. These abnormal vessels cause irregular blood flow and distribution, 
impaired oxygen delivery and impede immune cell function, which together lead to 
inefficient delivery of anti-cancer agents causing tumor cell resistance to radiation and 
chemotherapies3-5. Conventional anti-angiogenic therapies focus on either neutralizing the 
effect of soluble angiogenic factors such as vascular endothelial growth factor (VEGF) using 
specific antibodies or inhibiting VEGFR kinase activity6-8. These conventional anti-
angiogenic strategies showed only modest success in clinical trials due to the development 
of resistance (evasive or intrinsic) as tumor endothelial cells (TEC) became refractory to 
anti-VEGF therapy over time3-5. These findings led to the emergence of a new concept 
called “vascular normalization”, i.e. transient inhibition of tumor angiogenesis leading to 
normalization of tumor vasculature which improves the efficacy of chemo- and radio 
therapies 1, 2. Although vascular normalization combined with chemotherapy have shown 
transient benefits, clinically they failed to exhibit long term beneficial effects owing to these 
strategies still being focused onVEGF-targeted therapies, despite their shortcomings 2, 9, 10. 
Infact, recent positron emission tomograpy (PET) imaging results have demonstrated a rapid 
decrease in the delivery of chemotherapeutic drugs to tumors post anti-VEGF therapy, in 
non-small cell lung cancer (NSCLC) patients 11.Therefore, an urgent need arises for the 
development of novel vascular normalization strategies.
In addition to soluble stimuli, such as VEGF and PDGF (platelet derived growth factor) 
local mechanical cues conveyed by the extracellular matrix (ECM), due to cyclic 
deformation of blood vessels and hemodynamic forces, are also potent inducers of 
directional capillary growth and vascular remodeling in vitro and in vivo 12-16. Endothelial 
cells (ECs) sense mechanical forces associated with tissue distortion through integrin 
receptors that mediate their adhesion to the surrounding ECM12, 14, 15, 17. Unlike normal 
ECM, the tumor ECM becomes stiffer as a result of continuous remodeling of matrix 
components by tumor cells and stromal fibroblasts. Further, the tumor vasculature is hyper-
permeable due to irregular basement membrane and poor pericyte coverage and therefore 
releases plasma components into the surrounding extracellular space, eventually leading to 
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increased ECM stiffness. Cells sense changes in ECM stiffness through integrin receptors 
which transduce these mechanical signals into the cell through the actin cytoskeleton. As 
shown previously in tumor epithelial cells18, 19 and TEC20, this increase in ECM stiffness 
also feeds back to enhance integrin-mediated Rho/ROCK (Rho-associated kinase) activity 
and contraction that can lead to aberrant mechanosensitivity of TEC.
One of the earliest responses of cells to mechanical force is the influx of calcium through the 
activation of mechanosensitive ion channels21-23. Although activation of these channels is 
thought to be independent of integrin mechanosensing, several lines of evidence indicate that 
both integrins and mechanosensitive ion channels are well connected22, 24-28. We have 
previously shown that the application of cyclic strain to normal endothelial cells (NEC) 
induces cell reorientation through activation of mechanosensitive Transient Receptor 
Potential Vanilloid 4 (TRPV4) ion channel-dependent calcium influx, which in turn activates 
additional integrins and causes down-stream cytoskeletal reorganization16. Importantly, 
siRNA knockdown of TRPV4 channels inhibited mechanical strain-induced reorientation of 
NEC, thus confirming their key role in endothelial cell mechanosensitivity. Notably, 
endothelial cell mechanosensitivity strongly influences vascular formation and patterning20, 
and thus, tumor vessel malformations could arise from deregulation of TEC 
mechanosensing. Indeed, we have previously shown that TEC fail to reorient in response to 
cyclic strain, exhibit aberrant mechanosensitivity to ECM stiffness and undergo abnormal 
angiogenesis in vitro. Importantly, this abnormal TEC behavior resulted, at least in part, 
from abnormally high basal Rho activity20. However, the upstream signaling molecule or the 
molecular mechanism(s) governing high Rho-mediated aberrant mechanosensitivity and 
angiogenesis by TEC remain unknown. In the present study, we explored whether the 
mechanosensitive TRPV4 ion channel is a key determinant of TEC dysfunction leading to 
tumor angiogenesis and abnormal vasculature.
 Results
 Tumor endothelial cells express lower levels of TRPV4 and TRPV4-dependent calcium 
influx
We and others have previously shown that TRPV4 channels are functionally expressed in 
endothelial cells and act as mechanosensor of cyclic stretch and flow16, 29. We also 
demonstrated that TRPV4 channels induce mechanical force-dependent calcium influx in 
integrin specific manner in endothelial cells and this TRPV4-dependent 
mechanotransduction regulates cyclic strain–induced endothelial cell reorientation16. 
Interestingly, we found that tumor derived endothelial cells (TEC) failed to reorient in 
response to cyclic strain similar to that of TRPV4 knockdown endothelial cells suggesting 
TEC may mimic TRPV4 knockdown phenotype 20. Because mechanical force (cyclic 
strain)-induced reorientation in endothelial cells is dependent on TRPV4 channels16, we 
investigated whether these channels contribute to the abnormal mechanosensitivity of 
TEC20. TEC and normal EC (NEC) used in the present study have been isolated and 
characterized for EC markers, EC function and mechanosensing at different passages20, 30. 
We first compared TRPV4 expression levels between NEC and TEC using Western blot 
analysis. While NEC exhibited strong expression of TRPV4,16, 31 it was significantly lower 
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in TEC (Fig.1A, B). To determine the functional implications of lower TRPV4 expression in 
TEC, we measured calcium influx in Fluo-4/AM loaded cells, in response to the addition of 
specific TRPV4 activators, GSK1016790A or 4-α-PDD. By using calcium imaging, patch-
clamp, siRNA knockdown and TRPV4 null cells, we have previously demonstrated that 
these compounds specifically activates TRPV4-mediated calcium influx in endothelial 
cells16, 31. GSK1016790A (100 nM) induced calcium influx in both NEC and TEC but the 
influx in TEC was decreased by almost 40-50% compared to NEC (p≦0.001) (Fig.1C, D). 
Another TRPV4 agonist, 4-α-PDD (10 μM) also induced a rapid calcium influx in NEC, 
which was again significantly reduced by ∼40% (p≦ 0.01) in TEC (Supplementary Fig.S1 
A, B). These results demonstrate that TRPV4 expression and function (calcium influx) are 
impaired in TEC.
 Tumor Angiogenesis and tumor growth are enhanced in TRPV4 null mice
Next, to confirm if TRPV4 expression level contributes to tumor angiogenesis in vivo, we 
induced tumors in TRPV4 KO and WT mice (C57BL/6) by subcutaneously injecting mouse 
Lewis lung carcinoma cells (LLC). We found that tumor growth was 2-3 times greater in 
TRPV4 KO mice compared to WT mice at day 21 (Fig.2A). Importantly, 
immunohistochemical analysis revealed that tumors in TRPV4 KO mice exhibited a greater 
fraction of hyper-dilated (malformed) vessels with significantly larger vessel diameters 
(p≦0.05) compared to WT mice (Fig. 2, B, C). In contrast to tumor vessels in WT mice, 
those in TRPV4 KO mice exhibited poor pericyte coverage, as determined by very weak α-
SMA staining, indicating the immature nature of these vessels. (Fig. 2D, E). Further, the 
tumors from TRPV4 KO mice exhibited increased microvessel density compared to tumors 
from WT mice (Supplementary Fig.S2 A, B). Next, we assessed the leakiness of TRPV4 KO 
vessels by performing permeability assays using TRITC-dextran (3000 MW) perfusion, via 
tail vein injections. Immunohistochemical analysis revealed increased TRITC staining 
within the tumor tissue, surrounding the vessels, in TRPV4 KO mice compared to WT 
tumors suggesting that TRPV4KO vessels are indeed hyperpermeable (Suppl Fig.S3). Taken 
together, these results clearly suggest that TRPV4 plays a critical role in modulating tumor 
angiogenesis and the absence of TRPV4 can lead to abnormal tumor angiogenesis 
(immature (leaky) vessels), possibly through altered mechanotransduction exhibited by 
endothelial cells.
 TRPV4 overexpression restores mechanosensitivity and reduces abnormal cell 
migration in tumor endothelial cells
The above findings suggest that lower levels of TRPV4, a known mechanosensor in 
endothelial cells 16, 22, 32, 33 may contribute to the previously reported aberrant 
mechanosensitivity of TEC in response to ECM stiffness and cyclic strain 20. Since ECM 
stiffness is known to increase in tumors 19, which can also influence TEC spreading, 
migration and tube formation, we investigated if overexpression of TRPV4 might rescue the 
abnormal mechanosensitivity exhibited by TEC. To achieve this, we expressed a human 
TRPV4-EGFP construct in TEC; EGFP fluorescence revealed that more than 80% cells were 
transfected with TRPV4-EGFP (Supplementary Fig. S4A). We found that overexpression of 
TRPV4 increased GSK1016790A-induced calcium influx in TEC by almost 4-fold (p≦ 
0.01) compared to EGFP-alone expressing cells (Supplementary Fig.S4 B, C). The other 
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TRPV4 specific activator, 4-α-PDD, also increased calcium influx in these TRPV4-
transfected TEC cells compared to EGFP-expressing controls (not shown).
To explore if TRPV4 overexpression influences TEC mechanosensitivity towards ECM 
stiffness, we next cultured TRPV4-overexpressing TEC on transglutaminase linked gelatin 
gels of varying stiffness (370 and 2280 Pa; representing intermediate and high stiffness, 
respectively) which mimic the stiffness of tumor ECM 19 for 6 h and compared their degree 
of spreading20 with that of control EGFP-expressing cells (Fig. 3A, B). In past studies, we 
found that both NEC and TEC spread similarly on low stiffness (98 Pa) gels20. However, in 
that study, NEC exhibited increased spreading on intermediate stiffness (370 Pa) which 
reached plateau at high stiffness (2280 Pa) while TEC continue to increase their spreading 
with increased stiffness. Therefore, in the present study, we focused on intermediate (370 
Pa) and high (2280 Pa) stiffness gels. We found that NEC (expressing only EGFP) spread to 
similar extent on both intermediate and high stiffness gels (370 and 2280 Pa) further 
confirming that the spreading of NEC reached plateau at 370 Pa (Fig.3 A, B), similar to our 
previous study20. On the other hand, spreading of TEC (expressing only EGFP) was 
significantly more on high stiffness gels compared to intermediate stiffness gels (Fig.3 A,B). 
In contrast, TEC-TRPV4-EGFP exhibited reduced spreading on high stiffness gels 
compared to TEC-EGFP alone, with no significant difference between intermediate and high 
stiffness substrates (Fig. 3A, B) suggesting that TRPV4 overexpression restored substrate 
mechanosensitivity in these cells. We did not find any change in NEC spreading when 
TRPV4-EGFP was overexpressed (data not shown). To further confirm that TRPV4 
overexpression restores mechanosensitivity, we exposed TEC-EGFP and TEC-TRPV4-
EGFP cells to cyclic strain, which is widely used to test endothelial cell mechanosensitivity, 
as previously described16. As shown earlier20, we found that TEC-EGFP failed to reorient 
while TEC overexpressing TRPV4-EGFP significantly oriented in response to cyclic strain 
(data not shown).
Since cell migration is dependent on mechanosensing of matrix stiffness and is a critical 
component of angiogenesis, we next explored if TRPV4 overexpression which normalized 
mechanosensitivity also influence TEC migration. To demonstrate this, we chose substrates 
of intermediary stiffness, as they supported optimal TEC cell spreading with or without 
TRPV4 overexpression. Consistent with their abnormal mechanosensitivity, TEC exhibited 
high cell migration speed (40 μm/h; (Fig.3 C, D), which was significantly suppressed (10 
μm/h) when cells were transfected with TRPV4 (Fig.3 C, D). Further, we found that NEC 
migrated at a speed of 10 μm/h (Supplementary Fig.S5) suggesting that overexpression of 
TRPV4 normalized TEC cell migration to that of NEC. Taken together, all the above 
findings clearly demonstrate that TRPV4 expression restored mechanosensitivity in TEC 
and normalized migration.
 TRPV4 overexpression or pharmacological activation normalizes 
abnormal tube formation in vitro via modulation of Rho activity
Since TRPV4 overexpression restored TEC mechanosensitivity to ECM stiffness which 
reduced abnormal cell migration, we explored whether TRPV4 expression normalizes vessel 
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formation and if so, further determine the molecular mechanisms that underlie this process. 
First, TEC expressing TRPV4-EGFP or EGFP alone were tested for their ability to form 
capillary networks using a Matrigel® based in vitro 2D angiogenesis assays. We have 
previously shown that TEC form robust tubes when plated at low density (2 × 104 cells/ 
well) on Matrigel (2D) but at high density (8 × 104 cells/ well), these cells form tubes and 
then undergo multicellular retraction with disruption of tubular networks20. Importantly, 
TEC cultured within (rather than on top of) Matrigel formed tubular structures that were 
abnormally dilated and non-uniform, an abnormal morphology 20; (Fig. 4A) reminiscent of 
that observed within the cancer microvasculature in vivo, whereas NEC reorganized into 
tubular structures of relatively uniform size under similar culture conditions. These findings 
suggest that TEC are capable of tube formation in both 2D and 3D Matrigels. However, they 
collapse on 2D Matrigel due to high contraction mediated by cumulative high Rho 
activity 34, but form abnormal tubes in 3D. Therefore, we used both 2D and 3D Matrigel 
assays to determine if TRPV4 overexpression could normalize abnormal tube formation by 
TEC. To achieve this, first, we plated TEC expressing EGFP alone or overexpressing 
TRPV4 (expressing TRPV4-EGFP) at high density (8 × 104 cells/ well) on Matrigel for 2D 
tube formation. As expected, TEC expressing EGFP alone, formed tubes at high density (8 × 
104 cells/ well) but these formed tubes underwent multicellular retraction and collapsed (Fig.
4A). In contrast, TEC overexpressing TRPV4 formed a robust tubular network, with 
quantitative analysis revealing a significant increase (almost 10 fold) in tube length in 
TRPV4-expressing TEC compared to EGFP-expressing counterparts (Supplementary 
Fig.S6). Interestingly, we did not find any change in tube formation by NEC either 
expressing EGFP alone (Fig.4A) or overexpressing TRPV4-EGFP (not shown). We also 
found that TRPV4 overexpression normalized tube formation in 3D Matrigels (Fig4A).
Next, we examined if pharmacological activation of TRPV4 normalizes abnormal tube 
formation in vitro. For this, we activated TRPV4 in TEC using the small molecule activator 
of TRPV4, GSK1016790A (GSK; 100 nM). We found that, similar to TRPV4 
overexpression, TEC, but not NEC, treated with GSK formed robust tubes at high plating 
density (8 × 104 cells/ well) (Fig.4B). Since activity-dependent regulation of ion channels 
was shown in various cancers35, 36, we then asked if activation of TRPV4 with GSK 
modulates TRPV4 expression in TEC. We found that treatment of TEC with GSK for 24 h 
significantly increased TRPV4 protein expression (Fig. 4C). These results demonstrate that 
TRPV4 overexpression or pharmacological activation by GSK normalizes abnormal 
angiogenesis exhibited by TEC through the restoration of mechanosensitivity towards ECM 
stiffness and thus identifies TRPV4 as a critical mediator of angiogenesis.
To understand the molecular mechanism downstream of TRPV4 that mediates normalization 
of angiogenesis, we focused on Rho which regulates endothelial contraction that is required 
for partial rounding of endothelial cells during tube formation (34). We have previously 
demonstrated that TEC (expressing only EGFP) showed high basal Rho activity 20 which is 
the reason for abnormal collapse of TEC on 2D Matrigel, when plated at high densities. 
However, we found that overexpression of TRPV4-EGFP significantly reduced this high 
basal Rho activity exhibited by TEC (approximately ½-fold lower; p≦0.001) (Fig.4 D). We 
found that TRPV4 activator GSK1016790A (100 nM) also inhibited high basal Rho activity 
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in TEC (Supplementary Fig.S7) suggesting that TRPV4 is a critical modulator of Rho 
activity in TEC.
 TRPV4 specific small molecule activator GSK1016790A normalizes tumor vasculature in 
vivo and reduces tumor growth in combination with Cisplatin
Finally, we explored if pharmacological activation of TRPV4 induces tumor vascular 
normalization/maturation in vivo and improves efficacy of chemotherapeutic drug 
(Cisplatin). To achieve this, we injected TRPV4 activator GSK1016790A intraperitonially 
every day for 14 days in WT mice that had developed palpable tumors (around 100 mm3, 
after 7 days). Cisplatin was given once per week starting 2-4 days after GSK treatment and 
tumor growth was monitored every week until day 21. First, we examined vessel maturity in 
tumors by staining for pericyte coverage. We observed that the vessels in GSK and GSK-
Cisiplatin-treated tumors, but not in control or Cisplatin treated ones, showed increased 
pericyte coverage (Fig.5A, B) suggesting that TRPV4 activation normalized tumor 
angiogenesis and induced vessel maturation which may help efficient delivery of Cisplatin. 
Consistent with this observation, we found that tumor growth was markedly reduced in 
GSK-Cisplatin treated animals (Fig.5C), but not in control or Cisplatin treated mice, 
suggesting the improved delivery of Cisplatin due to the normalization of vessels by TRPV4 
activation.
 Discussion
Tumor angiogenesis has been widely shown to be regulated by soluble growth factors such 
as VEGF and fibroblast growth factor (FGF). However, regulation of tumor angiogenesis by 
mechanical forces is not well known. In the present study, we found that tumor endothelial 
cells express lower levels of TRPV4, a mechanosensitive ion channel, which is a key 
upstream signaling molecule that regulates tumor endothelial cell mechanosensitivity, tumor 
angiogenesis and tumor vessel maturation. Importantly, we demonstrate that overexpression 
of TRPV4 normalizes aberrant TEC mechanosensitivity, migration and angiogenesis through 
modulation of Rho activity. We further confirmed these findings in vivo by demonstrating 
that TRPV4 KO mice lacking this mechanosensing molecule exhibit severe tumor vessel 
malformations, characterized by increased vessel diameter, length and density, and enhanced 
tumor growth. Finally, we demonstrated that administration of the specific small molecule 
TRPV4 activator, GSK1016790A induced vessel maturation and, in combination with a 
chemotherapeutic drug, Cisplatin, reduced tumor growth in WT mice. To the best of our 
knowledge, this is the first report to demonstrate a role for TRPV4 in angiogenesis in vitro 
or in vivo.
TRPV4 channels are non-selective calcium ion channels ubiquitously expressed in 
endothelial cells that act as a mechanosensor of cyclic strain and shear stress in endothelial 
cells 16, 22, 29, 32, 33, 37. We have previously shown that endothelial cells express functional 
TRPV4 channels (Fluo-4 imaging, patch-clamp) and that these channels mediate mechanical 
signals from integrin to integrin that are critical for reorientation of NEC in response to 
cyclic strain 16. The fact that EC isolated from tumors fail to reorient in response to cyclic 
strain and exhibit aberrant mechanosensitivity towards substrate stiffness20, suggested that 
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TRPV4 channel signaling might be altered in these cells. Indeed, we found that TEC express 
low levels of functionally active TRPV4 channels compared to NEC. TRPV4 protein usually 
exhibits two bands that are below and above of 100 kDa in Western blots16,29,53-56. 
Although the upper band has been demonstrated to be the glycosylated form of TRPV453 
which influences its membrane translocation and activity, we did not find any significant 
difference in terms of the relative amount of each band in NEC or TEC, suggesting that 
TRPV4 expression is down-regulated. Consistently, TRPV4 expression has been shown to 
be modulated by microRNA -20357. However, it is not clear how tumor cells or tumor 
stroma may influence TRPV4 expression in TEC. Importantly, we demonstrate that TRPV4 
overexpression or pharmacological activation by a small molecular activator, restored 
mechanosensitivity to matrix stiffness and cyclic strain, reduced migration and normalized 
the abnormal angiogenesis exhibited by TEC in vitro.
The aberrant mechanosensitivity of TEC is known to be mediated by high basal Rho 
activity20; however, the molecular mechanism up-stream of Rho responsible for this 
abnormal behavior is not yet known. Here, we show that overexpression of TRPV4 
significantly inhibited high basal Rho activity in TEC. This reduction in basal Rho activity 
could possibly inhibit the high basal contraction of TEC 34 which then may be responsible 
for the restored mechanosensitivity of these cells towards substrate stiffness and 
normalization of angiogenesis. In fact, transient inhibition of Rho kinase with Y-27632 can 
normalize TEC responses to cyclic strain20. Although the exact molecular mechanism 
through which TRPV4 regulates Rho activity is not known, it is plausible that TRPV4 exerts 
its effects by modulating integrin activation, which has been shown to be sensitive to 
mechanical force-induced TRPV4-dependent calcium influx16. Importantly, binding of 
integrins to ECM transiently inhibit Rho activity38, 39 and facilitate cell shape changes, 
leading to cell spreading and reorientation. Interference with binding of additional integrins 
using function blocking antibodies also significantly inhibits TRPV4-dependent cyclic 
strain-induced CE reorientation16.
Although TRPV4 role in endothelial migration was shown 40, the role of TRPV4 in 
physiological or pathological angiogenesis is not demonstrated. Our results demonstrating 
TRPV4 overexpression normalized tube/vessel formation in 2D Matrigels, coupled with 
increased vessel malformations and enhanced tumor growth in TRPV4 KO mice, confirms 
that TRPV4 plays a critical role in tumor angiogenesis. Further, combination of GSK and 
Cisplatin, but not each them alone, inhibited tumor growth suggesting that TRPV4 
activation-induced vascular maturation improved the efficacy of Cisplatin. These findings 
have significant value in vascular normalization therapies directed towards the treatment of 
cancer. Since the initial proposal that tumors rely on neovascularization for their survival and 
growth41, 42, angiogenesis has become a potential target for cancer therapy. In fact, multiple 
angiogenesis inhibitors have now been identified, and some clinically approved (e.g., 
Avastin), that inhibit the growth of a wide variety of experimental tumors in many animal 
models albeit with limited success in patients. Although VEGF is required for normal 
proliferation and migration of EC, it is important to emphasize that the tumor vasculature in 
certain cancers, such as in renal cell carcinoma, is largely refractory to therapies designed to 
alter VEGF signaling, as growth factors are redundant for angiogenesis 3-6, 43. Nevertheless, 
current vascular normalization therapies still focus on targeting soluble growth factors such 
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as VEGF and PDGF 2, 10, 44-51. Notably, recently it was shown NSCLC patients treated with 
humanized VEGF antibody, bevacizumab reduced both perfusion and net influx rate of 
[(11)C] docetaxel within 5 h as measured by PET. Further, it was demonstrated that these 
effects persisted even after 4 days11. Importantly, these findings show no evidence for a 
substantial improvement in drug delivery to tumors by anti-VEGF treatment and highlight 
the importance of drug scheduling and supports further studies to optimize scheduling or the 
use of anti-angiogenic drugs.
Thus, our results showing that a mechanosensitive ion channel, TRPV4 regulates tumor 
angiogenesis through the modulation of Rho-dependent mechanosensitivity of TEC and, a 
small molecule activator of TRPV4, GSK1016790A together with Cisplatin, inhibits tumor 
growth, suggests TRPV4 as a target for developing a novel mechanotransduction-based 
therapy for vascular normalization. To our knowledge, TRPV4 channels have not previously 
been studied as potential therapeutic targets in angiogenesis, therefore we believe that 
elucidation of TRPV4-dependent mechanotransduction mechanisms and their role in 
angiogenesis may open entirely new avenues for developmental therapeutics for cancer as 
well as other angiogenic disorders, such as age-related macular degeneration and diabetic 
retinopathy.
 Materials and Methods
 Cell culture
Normal (NEC) and Tumor (TEC) endothelial cells were obtained from a transgenic 
adenocarcinoma mouse prostate (TRAMP) model, as previously described20, 30. Cells were 
plated on fibronectin (FN) or gelatin-coated tissue culture dishes and grown in a defined 
medium composed of low glucose DMEM, 10% fetal bovine serum, 10% Nu Serum IV, 
VEGF(1ng/ml) basic fibroblast growth factor (3 ng/ml), heparin salt (0.1 mg/ml), 1% 
insulin-transferrin-selenium and antibiotic/mycotic mix. Cells were cultured in a 37°C, 
5%CO2 incubator, split at ∼90-95% confluence, and used between passages 11-22. These 
cells (NEC and TEC) were characterized for the presence of endothelial markers and 
function. We found that both of these cells expressed endothelial markers including 
CD31(PECAM-1), VE-cadherin, Von Wildebrand Factor (vWF), endothelial nitric oxide 
synthase (eNOS) and bind to isolectin-IB4 as measured by FACS, Western blotting, RT-PCR 
and immunocytochemistry. In contrast, these cells do not express mesenchymal markers α-
SMA and PDGFR-β receptor20, 30. NEC and TEC formed robust tubular structures/sprouts 
in 2D and 3D Matrigel/Fibrin gel angiogenesis assays further confirming that these are 
functional EC 20, 30. We have shown these EC retained their endothelial phenotype and 
TRPV4 expression (not shown) even up to 22 passages20.
 Transfection
Cells were transfected with TRPV4-EGFP (kind gift of Dr. Jendrach, Germany) or EGFP 
constructs using targefect (targetingsystems)31. The transfection efficiency was found to be 
80-90%.
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 Cell spreading on flexible substrates
Transglutaminase-crosslinked gelatin hydrogels of increasing stiffness were prepared using 
3, 5 and 10% (w/v) final gelatin concentration and incubated at 4°C overnight to stabilize 
crosslinking (19). Cells in regular culture medium were plated at low density (to minimize 
cell-cell interactions) and allowed to spread for 6 h.
 Rho activation assay
Rho activity was determined using the Rhotekin-RBD affinity precipitation assay as 
described previously20, 52. Briefly, TEC overexpressing TRPV4-EGFP or EGFP alone or 
TEC treated with GSK1016709A (Sigma-Aldrich; 100 nM for 15 min) were lysed in 1% 
Triton X-100 buffer and centrifuged at 12000× g for 15 min. Equal volumes (compensated 
for equal protein concentration) of clarified lysate were incubated with GST-Rhotekin-RBD 
beads (Cytoskeleton Inc.), for 1 h at 4°C. The beads were collected by centrifugation and 
washed 3 times with wash buffer. The bound GTP-Rho was extracted with SDS-sample 
buffer and was detected using Rho mAb (SantaCruz) on a Western blot. GTP-Rho levels 
were calculated from the densitometric analyses of Western blot and normalized to the levels 
of total-Rho and presented as relative Rho activity with that of TEC transfected with EGFP 
alone or TRPV4-EGFP.
 Calcium Imaging
TEC overexpressing TRPV4-EGFP or EGFP alone or NEC were cultured on MatTek glass 
bottom dishes and loaded with Fluo-4/AM (1-4 μM) for 30 min, washed 3 times in calcium 
medium (136 mM NaCl, 4.7 mM KCl,1.2 mM MgSO4, 1.1 mM CaCl2, 1.2 mM KH2PO4, 5 
mM NaHCO3, 5.5mM glucose, and 20 mM Hepes. pH 7.4). Cells were stimulated with 
TRPV4 activators 4-α-PDD (Sigma-Aldrich; 10 μM) or GSK1016790A (100 nM) in 
calcium medium16, 22, 31. Calcium imaging was performed on Leica SP2 Confocal 
Microscope or Olympus FluoView 300 confocal microscope and analyzed using Leica/
Olympus software and Microsoft Excel. We have previously confirmed that TRPV4 
channels are expressed in WT and NEC and that TRPV4 activators 4-α-PDD (10 μM) or 
GSK1016790A (100 nM) specifically induce calcium influx in TRPV4 expressing but not 
TRPV4 null endothelial cells in the calcium containing media31.
 SDS-PAGE and Western blot analysis
Cells were lysed in TritonX-100 with protease and phosphatase inhibitor cocktail (Boston 
Bioproducts). Cell lysates were separated by electrophoresis on 8% SDS- polyacrylamide 
gels and transferred to Immobilon ® polyvinylidene difluoride membrane. The membrane 
was blocked in 5% milk in TBS with 0.1% Tween-20 (TBS-Tw) for 1 h. The blot was then 
incubated with the following primary antibodies anti-TRPV4 (1:300) (Alomone), anti-Actin 
(1:1000). The ECL (Pierce West Pico) method was used with anti-rabbit (Jackson 
Laboratories) at a dilution of 1:10,000 and developed using Kodak X-ray film or Protein 
Simple. Results were quantified using Image J software.
Adapala et al. Page 10
Oncogene. Author manuscript; available in PMC 2016 July 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
 In vitro angiogenesis assays
Growth factor-reduced Matrigel® (BD Biosciences) was plated on 48 well plates and kept at 
37°C in an incubator for 30 min. Cells overexpressing TRPV4-EGFP or EGFP alone (2-8 × 
104 cells/well) were plated on Matrigel and incubated at 37°C for 16-18 h20. For 2D assays 
performed in the presence or absence of TRPV4-specific agonist, cells were treated with 
GSK1016790A (100nM) prior to plating. Tube formation was quantified by obtaining 
images as described below.
 Microscopy, image analysis and statistics
The expression of EGFP-TRPV4 in EC was visualized using a Nikon Eclipse TE 2000-E 
microscope (Nikon, Japan) fitted with a CoolSnap HQ digital camera (Photometrics) or 
Olympus IX72 fluorescence microscope (Olympus, Japan). The cells spread on flexible 
gelatin hydrogels were fixed with 4% paraformaldehyde while cells forming tubular 
structures were left untreated, and samples from both studies were imaged using a Nikon 
Diaphot 300 phase contrast microscope (Nikon, Japan) fitted with a Hamamatsu digital 
camera (Hamamatsu Photonics, Japan) or Olympus IX72 fluorescence microscope 
(Olympus, Japan). Image analyses were performed using ImageJ software (NIH). For cell 
spreading studies, TEC cell areas were measured by tracing cell perimeter and normalized as 
described previously20. At least 30 cells were evaluated. For cell migration experiments, live 
cell images were recorded with a CCD camera (Hamamatsu, Tokyo, Japan) on a Nikon 
Eclipse TE 2000-E microscope (Nikon, Japan) or Olympus IX81 fluorescence microscope 
(Olympus, Japan) equipped with phase contrast optics and processed using the Image J. The 
microscope was also equipped with an on-stage heater that maintained the temperature at 
37°C at all times, and the culture medium was covered with a thin layer of mineral oil to 
prevent evaporation. Cell migration was measured by marking the centroids of the migrating 
cell recorded at 20 min intervals over 2 h and then used to calculate the speed of cell 
migration. All data are expressed as mean ± SEM and evaluated for differences using 
student's t-test and/or one-way ANOVA.
 Syngeneic tumor model in mice and analysis of tumor growth, vascular malformation 
and angiogenesis
All the experiments were performed according to approved protocol by Northeast Ohio 
Medical University, IACUC. Mouse Lewis lung carcinoma (LLC) cells (2 × 106) were 
subcutaneously injected in the flank region of wild type C57BL/6 mice (WT) or TRPV4 
knockout mice in C57BL/6 background (KO). Tumor size was measured using calipers at 7, 
14 and 21 days and tumor volume was calculated according to the formula V= 
4/3*Pi*Length/2*(width/2)2. At day 21, mice were euthanized and tumor tissues were 
collected and fixed for immunohistochemistry or stored at -80°C. To measure tumor 
angiogenesis, tumor tissue sections of 10 μm thicknesses were stained with anti-CD31 
(PECAM-1) to visualize the microvessels, α-SMA to stain pericytes and DAPI to label the 
nuclei. Images were acquired using Olympus IX72 microscope and the microvessels density, 
diameter (Feret) and length were calculated using Image J software. For the in vivo drug 
experiments, six to eight mice/group were used and the animals were divided in to four 
groups: 1) WT (control) 2) WT + TRPV4 activator 3) WT + Cisplatin and 4) WT + TRPV4 
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activator + Cisplatin. Once the tumors were palpable (after 7 days), the mice were daily 
given an intraperitonial (i.p) injection of TRPV4 agonist GSK1016790A (10 μg/kg) to 
groups 2 and 4 until day 21. The anti-cancer drug Cisplatin (3 mg/kg/week) was 
administered i.p. once/week to groups 3, and 4, 3 days post treatment with TRPV4 activator, 
until day 21. The WT control received saline as a vehicle.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig.1. TRPV4 channel expression and function in normal and tumor endothelial cells
A) Western blot analysis of TRPV4 expression in normal (NEC) and tumor-derived 
endothelial cells (TEC). B) Quantitative analysis of the Western blots showing significant 
(p≦0.05) reduction in TRPV4 expression in TEC. C) Representative traces showing relative 
changes in cytosolic calcium in response to a selective TRPV4 agonist, GSK1016790A (100 
nM) in Fluo-4 loaded normal and tumor endothelial cells (n=300). Arrow denotes the time 
when the cells were stimulated with the TRPV4 agonist D) Quantitative analysis of cytosolic 
calcium influx induced by GSK1016790A in NEC and TEC. (F/F0 = ratio of normalized 
Fluo-4 fluorescence intensity relative to time 0). The results shown are mean ± SEM from 3 
independent experiments. The significance was set at p≦ 0.05.
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Fig.2. Vessel malformations and tumor growth are enhanced in TRPV4 knockout mice
A) Time-dependent growth of the tumors in WT and TRPV4KO mice. Mouse Lewis lung 
carcinoma (LLC) cells (2 × 106) were subcutaneously injected in to wild type C57BL/6 mice 
(WT) or TRPV4 knockout mice in C57BL/6 background (TRPV4KO) and tumor growth 
was measured using calipers at indicated days. The data shown are ± SEM of three 
independent experiments (n=8-10 mice for each group). B) Immunohistochemical analysis 
showing increased vessel diameter (feret) in tumors (21 days) from TRPV4 knockout mice 
(TRPV4KO) compared to wild type mice (WT). C) Quantitative analysis of microvessel 
diameter in tumors from WT and TRPV4KO mice. D) Frozen sections of tumors (10 μm 
thickness) were stained with CD31 (green) and α-SMA (red) to measure pericyte coverage 
(matured vessels). E) Quantitative analysis of pericyte covered microvessels in tumors from 
WT and TRPV4KO mice. The results shown are mean ± SEM from 3 independent 
experiments. The significance was set at p≦ 0.05.
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Fig.3. TRPV4 overexpression restores mechanosensitivity towards ECM stiffness, and reduces 
migration in TEC
A) Representative images showing normal (NEC) and tumor (TEC) endothelial cell 
spreading (indicative of mechanosensitivity) on intermediate (370 Pa) and high (2280 Pa) 
stiffness ECM gels. Cells were transfected with either EGFP alone or TRPV4-EGFP B) 
Quantitative analysis of projected cell areas of NEC and TEC (expressing EGFP alone) and 
TEC+TRPV4 (expressing TRPV4-EGFP) on ECM gels of intermediate and high stiffness 
(370 and 2280 Pa). The results shown are mean ± SEM from 3 independent experiments. 
The significance was set at p≦ 0.05. NS= non-significant. C) Time lapse phase contrast 
micrographs showing migration of TEC-EGFP (TEC) and TEC+TRPV4-EGFP (TEC
+TRPV4) cells plated on the surface of ECM gels of 370 Pa stiffness. Cells were allowed to 
spread for 4 h at 37°C and later shifted on to a microscope stage and random cell migration 
was recorded every 10 min using time lapse microscopy. Dashed line denotes the border of 
the leading edge at time 0. D) Quantification of cell migration as measured by marking the 
centroid of migrating cells overtime. Note: NEC migrated with a speed of 10 μm/h 
(Supplementary Fig.S5) suggesting that overexpression of TRPV4 normalized TEC 
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migration. The results shown are mean ± SEM from 3 independent experiments. The 
significance was set at p≦ 0.05.
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Fig.4. TRPV4 overexpression normalizes abnormal angiogenesis by tumor EC through the 
inhibition of abnormal Rho activity
A) Phase contrast micrographs showing the normalizing effects of TRPV4 overexpression 
on TEC angiogenic behavior when plated on 2D Matrigels (at high densities; 8 × 104 well 
that cause collapse of tubular networks) and 3D Matrigels. NEC-EGFP (NEC), TEC-EGFP 
(TEC) and TEC-TRPV4-EGFP (TEC+TRPV4) cells were plated and cultured on the surface 
of Matrigel for 18 h (2D) or mixed in Matrigel and cultured for 14 days (3D). Note that the 
overexpression of TRPV4 in TEC cells restored tube formation on 2D Matrigel and 
normalized abnormal tubes in 3D Matrigel. Scale bar= 10 μm. B) Phase contrast 
micrographs showing the normalizing effects of pharmacological activation of TRPV4 with 
GSK1016790A (100 nM) on TEC angiogenic behavior when plated on 2D (at high 
densities; 8 × 104/ well that cause collapse of tubular networks). Scale bar= 10 μm. C) 
Representative Western blot showing TRPV4 expression in TEC untreated or treated with 
GSK1016790A (100 nM) for 24 h. Densitometry analysis of relative changes in TRPV4 
expression measured by normalizing the levels of TRPV4 with that of tubulin. D) 
Representative Western blot showing the levels of active-Rho and total Rho for TEC and 
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TEC+TRPV4 cells. Rho activity was analyzed in TEC (EGFP) and TEC+TRPV4 cells 
cultured under regular growth conditions using the Rhotekin-RBD binding assay. 
Densitometry analysis of relative changes in Rho activity. Rho activity levels were measured 
by normalizing the levels of active Rho with that of total Rho.
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Fig.5. TRPV4 activation with a small molecule activator together with Cisplatin reduces tumor 
growth in WT mice
A) Syngeneic tumors (LLC) were injected in the back of WT (C57BL/6) mice and tumor 
growth was monitored for 21 days. TRPV4 activator, GSK1016790A (GSK) was injected 
i.p. everyday starting from day 7 (after palpable tumors were observed) until 21 days. 
Cisplatin was injected i.p. (once/week) 3 days after the injection of GSK1016790A. Frozen 
sections of tumors (10 μm thickness; from 21 day) were stained with CD31 (green) and α-
SMA (red) to measure pericyte coverage (matured vessels). B) Quantitative analysis of 
pericyte covered microvessels in tumors from control, GSK, Cisplatin, and GSK + Cisplatin 
treated mice. The results shown are mean ± SEM from 3 independent experiments. The 
significance was set at p≦ 0.05. C) Tumor volumes among mice groups. Note that tumor 
growth was reduced in GSK + Cisplatin (*) treated mice. However, treatment with either of 
the drug alone did not inhibit tumor growth, indicating that GSK treatment improved 
Cisplatin delivery through the normalization of the abnormal tumor vasculature.
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